Callahan Advisors LLC trimmed its stake in shares of CVS Health Corp (NYSE:CVS) by 23.6% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 26,367 shares of the pharmacy operator’s stock after selling 8,153 shares during the quarter. Callahan Advisors LLC’s holdings in CVS Health were worth $2,144,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other large investors have also recently bought and sold shares of the business. Horan Capital Advisors LLC. increased its position in shares of CVS Health by 3.2% in the 2nd quarter. Horan Capital Advisors LLC. now owns 32,115 shares of the pharmacy operator’s stock valued at $2,584,000 after buying an additional 1,000 shares in the last quarter. Community Bank N.A. increased its position in shares of CVS Health by 7.3% in the 2nd quarter. Community Bank N.A. now owns 19,976 shares of the pharmacy operator’s stock valued at $1,608,000 after buying an additional 1,362 shares in the last quarter. FIL Ltd increased its position in shares of CVS Health by 13.8% in the 2nd quarter. FIL Ltd now owns 514,836 shares of the pharmacy operator’s stock valued at $41,424,000 after buying an additional 62,318 shares in the last quarter. Midwest Investment Management LLC increased its position in shares of CVS Health by 6.2% in the 2nd quarter. Midwest Investment Management LLC now owns 21,382 shares of the pharmacy operator’s stock valued at $1,720,000 after buying an additional 1,245 shares in the last quarter. Finally, Fiduciary Trust Co. boosted its stake in CVS Health by 1.2% in the 1st quarter. Fiduciary Trust Co. now owns 366,007 shares of the pharmacy operator’s stock worth $28,732,000 after purchasing an additional 4,265 shares during the period. 81.62% of the stock is currently owned by hedge funds and other institutional investors.
CVS Health Corp (CVS) opened at $78.78 on Friday. CVS Health Corp has a fifty-two week low of $66.45 and a fifty-two week high of $84.72. The company has a market cap of $79,800.00, a price-to-earnings ratio of 16.28, a PEG ratio of 1.25 and a beta of 0.90. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.55 and a current ratio of 1.05.
CVS Health (NYSE:CVS) last announced its earnings results on Monday, November 6th. The pharmacy operator reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.49 by $0.01. CVS Health had a net margin of 2.77% and a return on equity of 16.96%. The business had revenue of $46.18 billion during the quarter, compared to the consensus estimate of $46.17 billion. During the same quarter last year, the firm earned $1.64 earnings per share. CVS Health’s quarterly revenue was up 3.5% on a year-over-year basis. research analysts forecast that CVS Health Corp will post 5.89 EPS for the current year.
The business also recently declared a quarterly dividend, which will be paid on Friday, February 2nd. Shareholders of record on Wednesday, January 24th will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 2.54%. The ex-dividend date is Tuesday, January 23rd. CVS Health’s dividend payout ratio (DPR) is currently 41.32%.
A number of equities analysts recently weighed in on the stock. Loop Capital cut their target price on shares of CVS Health from $83.00 to $73.00 and set a “hold” rating for the company in a research note on Tuesday, November 7th. Morgan Stanley raised shares of CVS Health from an “equal weight” rating to an “overweight” rating and set a $88.00 price target on the stock in a report on Friday, January 5th. Needham & Company LLC increased their price target on shares of CVS Health from $85.00 to $88.00 and gave the company a “buy” rating in a report on Tuesday, January 2nd. SunTrust Banks increased their price target on shares of CVS Health to $90.00 and gave the company a “buy” rating in a report on Friday, January 5th. Finally, Jefferies Group lowered their target price on shares of CVS Health from $86.00 to $76.00 and set a “hold” rating on the stock in a report on Tuesday, November 7th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, twelve have issued a buy rating and two have assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $86.66.
In related news, EVP Lisa Bisaccia sold 29,445 shares of the business’s stock in a transaction dated Thursday, December 21st. The shares were sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the transaction, the executive vice president now directly owns 15,556 shares in the company, valued at $1,166,700. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 0.61% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this news story on another website, it was illegally copied and republished in violation of U.S. & international copyright & trademark laws. The original version of this news story can be read at https://www.thelincolnianonline.com/2018/01/14/cvs-health-corp-cvs-shares-sold-by-callahan-advisors-llc-updated-updated.html.
About CVS Health
CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.